Neurocrine Biosciences Inc (NBIX) - Total Liabilities
Based on the latest financial reports, Neurocrine Biosciences Inc (NBIX) has total liabilities worth $1.38 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Neurocrine Biosciences Inc - Total Liabilities Trend (1996–2025)
This chart illustrates how Neurocrine Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore NBIX strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Neurocrine Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Neurocrine Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KT&G Corp
KO:033780
|
Korea | ₩5.37 Trillion |
|
Pro Medicus Ltd
AU:PME
|
Australia | AU$144.99 Million |
|
Samsung Heavy Industries
KO:010140
|
Korea | ₩10.85 Trillion |
|
Zhejiang Satellite Petrochemical Co Ltd
SHE:002648
|
China | CN¥39.17 Billion |
|
Industrivarden AB ser. C
ST:INDU-C
|
Sweden | Skr7.93 Billion |
|
CNH Industrial N.V.
NYSE:CNH
|
USA | $34.17 Billion |
|
Toromont Industries Ltd.
TO:TIH
|
Canada | CA$2.21 Billion |
Liability Composition Analysis (1996–2025)
This chart breaks down Neurocrine Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Neurocrine Biosciences Inc total assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neurocrine Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neurocrine Biosciences Inc (1996–2025)
The table below shows the annual total liabilities of Neurocrine Biosciences Inc from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.38 Billion | +22.09% |
| 2024-12-31 | $1.13 Billion | +10.75% |
| 2023-12-31 | $1.02 Billion | +54.24% |
| 2022-12-31 | $660.90 Million | -5.38% |
| 2021-12-31 | $698.50 Million | +14.79% |
| 2020-12-31 | $608.50 Million | -9.06% |
| 2019-12-31 | $669.10 Million | +30.59% |
| 2018-12-31 | $512.39 Million | +15.03% |
| 2017-12-31 | $445.45 Million | +787.20% |
| 2016-12-31 | $50.21 Million | -0.24% |
| 2015-12-31 | $50.33 Million | +46.59% |
| 2014-12-31 | $34.33 Million | +0.20% |
| 2013-12-31 | $34.27 Million | -17.64% |
| 2012-12-31 | $41.61 Million | -46.85% |
| 2011-12-31 | $78.29 Million | -37.41% |
| 2010-12-31 | $125.08 Million | +87.06% |
| 2009-12-31 | $66.86 Million | -17.87% |
| 2008-12-31 | $81.41 Million | -48.46% |
| 2007-12-31 | $157.96 Million | +110.72% |
| 2006-12-31 | $74.96 Million | -19.41% |
| 2005-12-31 | $93.02 Million | -25.82% |
| 2004-12-31 | $125.39 Million | -23.47% |
| 2003-12-31 | $163.84 Million | +287.45% |
| 2002-12-31 | $42.28 Million | +17.60% |
| 2001-12-31 | $35.96 Million | +58.02% |
| 2000-12-31 | $22.75 Million | +77.77% |
| 1999-12-31 | $12.80 Million | +50.59% |
| 1998-12-31 | $8.50 Million | -2.30% |
| 1997-12-31 | $8.70 Million | +67.31% |
| 1996-12-31 | $5.20 Million | -- |
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESS… Read more